Killing 84 birds with one stone.

Syntheses of natural product–like compound libraries with high scaffold diversity have proven hard to develop. A strategy employing metathesis cascades to 'zip up' a set of unsaturated building blocks differently connected by variable linkers demonstrates that over 80 distinct scaffold classes can be synthesized in one go.

[1]  Herbert Waldmann,et al.  From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.

[2]  J. Ngamphaiboon.  Montelukast in general pediatric practices. , 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[3]  Stuart L Schreiber,et al.  A planning strategy for diversity-oriented synthesis. , 2004, Angewandte Chemie.

[4]  Herbert Waldmann,et al.  Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Fok,et al.  Steroid fears in children with eczema , 2006, Acta paediatrica.

[6]  C. Bachert,et al.  Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. , 2006, Respiratory medicine.

[7]  W. Storms.  Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction , 2007, Expert opinion on pharmacotherapy.

[8]  D. Scow,et al.  Leukotriene inhibitors in the treatment of allergy and asthma. , 2007, American family physician.

[9]  Adam Nelson,et al.  Synthesis of Natural-Product-Like Molecules with Over Eighty Distinct Scaffolds** , 2008, Angewandte Chemie.

[10]  A. Nayak.  A review of montelukast in the treatment of asthma and allergic rhinitis , 2004, Expert opinion on pharmacotherapy.

[11]  A. Murray,et al.  Allergic rhinitis and recurrent epistaxis in children. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  T. Leung,et al.  Montelukast in the treatment of children with moderate‐to‐severe atopic dermatitis:
A pilot study , 2001, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[13]  K. Hon,et al.  Brief case series: Montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis , 2005, The Journal of dermatological treatment.

[14]  Herbert Waldmann,et al.  From protein domains to drug candidates – natural products as guiding principles in , 2002 .

[15]  A. Bener,et al.  Montelukast treatment in children with moderately severe atopic dermatitis. , 2007, European annals of allergy and clinical immunology.